Amersham targets Alzheimer's disease
British pharmaceutical and life sciences company Amersham has obtained an exclusive license from the University of Pittsburgh to a class of molecules that target amyloid plaque in the brain, the cause of Alzheimer's disease. Amersham will attempt to
British pharmaceutical and life sciences company Amersham has obtained an exclusive license from the University of Pittsburgh to a class of molecules that target amyloid plaque in the brain, the cause of Alzheimer's disease. Amersham will attempt to develop PET agents for diagnosing and monitoring the progress of the disease. Such agents could accelerate the development of a wide range of therapeutics for Alzheimer's by allowing doctors to definitively measure the effectiveness of a potential therapy, according to the company.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
AI-Initiated Recalls After Screening Mammography Demonstrate Higher PPV for Breast Cancer
March 18th 2025While recalls initiated by one of two reviewing radiologists after screening mammography were nearly 10 percent higher than recalls initiated by an AI software, the AI-initiated recalls had an 85 percent higher positive predictive value for breast cancer, according to a new study.
